Involvement of type A monoamine oxidase in neurodegeneration: Regulation of mitochondrial signaling leading to cell death or neuroprotection

Journal of Neural Transmission, Supplement

Volumn , Issue 71, 2006, Pages 67-77

  Naoi, M ^a   Maruyama, W ^b   Akao, Y ^a   Yi, H ^a   Yamaoka, Y ^a  

^a GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; COMPLEMENTARY DNA; DOPAMINE; HYDROGEN PEROXIDE; MONOAMINE OXIDASE INHIBITOR; QUINONE DERIVATIVE; RASAGILINE; SALSOLINOL; SUPEROXIDE; ENZYME INHIBITOR; INDAN DERIVATIVE; PROTEIN BCL 2; SALSOLINE; SALSOLINE DERIVATIVE; SEROTONIN; SMALL INTERFERING RNA; TETRAHYDROISOQUINOLINE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; AUTOOXIDATION; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; NERVE DEGENERATION; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; METHODOLOGY; MITOCHONDRIAL MEMBRANE; NEUROBLASTOMA; RADIATION EXPOSURE; TUMOR CELL LINE;

CELL DEATH; CELL LINE, TUMOR; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; INDANS; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; MONOAMINE OXIDASE; NERVE DEGENERATION; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SALSOLINE ALKALOIDS; SEROTONIN; SIGNAL TRANSDUCTION; TETRAHYDROISOQUINOLINES; TRANSFECTION;

EID: 34248549035     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-33328-0_8     Document Type: Article

References (49)

1. Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MBH, Tsujimoto Y, Naoi M (2002a) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl- 1(R)-aminoindan. J Neurochem 82: 913-923
2. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MBH, Naoi M (2002b) An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 326: 10510-10518
3. Andersen JK (2004) Oxidative stress in neurodegeneration: cause or consequence? Nature Med 10: S18-S25
4. Bach AWJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan S-W, Seeburg PH, Shih JC (1988) cDNA cloning of human monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85: 4934-4938
5. Bindokas VP, Jordan J, Lee CC, Miller RJ (1996) Superoxide production in rat hippocampal neurons: Selective imaging with hydroethidine. J Neurosci 16: 1324-1336
6. Bossy-Wetzel E, Schwarzenbacher R, Lipton S (2004) Molecular pathways to neurodegeneration. Nature Med 10: S2-S9
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein dye binding. Anal Biochem 72: 248-254
8. Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, Youdim MBH (2000) Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67: 577-585
9. Cases O, Seif I, Grimsby J, Gaspa P, Chen K, Pounin S, Müller U, Aguet M, Babinet C, Shih JC, De Maeyer E (1995) Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 268: 1763-1766
10. Cohen G, Farooqui R, Kesler N (1997) Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci USA 94: 4890-4897
11. Crompton M (1999) The mitochondrial permeability transition pore and its role in the cell death. Biochem J 341: 233-249
12. Crow JP (1997) Dichlorodihydrofluorescein and dihydrorhodamine 123 are selective indicators of peroxynitrite in vitro: Implications for intracellular measurement of reactive nitrogen and oxygen species. Nitric Oxide 1: 145-157
13. Damier P, Kastner A, Agid Y, Hirsch EC (1996) Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Neurology 46: 1262-1269
14. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Amtonsson B, Martinou J-C (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144: 891-901
15. DeZutter GS, Davis RJ (2001) Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc Natl Acad Sci USA 98: 6168-6173
16. Eckert A, Steiner B, Marques C, Leutz S, Roming H, Haass C, Muller WE (2001) Elevated vulnerability to oxidative tress-induced cell death and activation of caspase-3 by the Swedish amyloid precursor protein mutation. J Neurosci Res 64: 183-192
17. 2 imidazoline ligands in intact cells. Mol Pharmacol 51: 637-643
18. Götz MF, Freyberger A, Riederer P (1990) Oxidative stress: a role in the pathogenesis of Parkinson's disease. J Neural Transm [Suppl 29]: 241-249
19. Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305: 626-269
20. Heikkila RE, Manzimo L, Cabbat FS, Duvoisin RC (1985) Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,5- tetrahydropyridine by monoamine oxidase B. J Neurochem 45: 1049-1054
21. Kraml M (1965) A rapid microfluorometric determination of monoamine oxidase. Biochem Pharmacol 14: 1684-1686
22. Lan NC, Chen C, Shih JC (1989) Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells. J Neurochem 52: 1625-1634
23. Lim LCC, Powell JF, Murray R, Gill M (1994) Monoamine oxidase A gene and bipolar affective disorder. Am J Hum Genet 54: 1122-1124
24. Malorni W, Giammarioli AM, Matarrese P, Piertrangeli P, Agostinelli E, Ciaccio A, Grassilli E, Mondovi N (1998) Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett 426: 155-159
25. Marcocci L, De Marchi U, Salvi M, Milella ZG, Nocera S, Agostinelli E, Mondovi B, Toninello A (2002) Tyramine and monoamine oxidase inhibitors as modulators of the mitochondrial membrane permeability transition. J Membrane Biol 188: 23-31
26. Maruyama W, Abe T, Tohgi H, Dostert P, Naoi M (1996) A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in Parkinsonian cerebrospinal fluid. An Neurol 40: 119-122
27. Maruyama W, Naoi M, Kasamatsu T, Hashizume Y, Takahashi T, Kohda K, Dostert P (1997) An endogenous dopaminergic neurotoxin, N-methyl-( R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J Neurochem 69: 322-329
28. Maruyama W, Akao Y, Youdim MBH, Davis BA, Naoi M (2001a) Transfection-forced Bcl-2 overexpression and anti-Parkinson drug, rasagiline, prevent nuclear translocation of glyceraldehydes-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R) salsolinol. J Neurochem 78: 727-735
29. Maruyama W, Boulton AA, Davis BA, Dostert P, Naoi M (2001b) Enantiospecific induction of apoptosis by an endogenous neurotoxin N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. J Neural Transm 108: 11-24
30. Maruyama W, Youdim MBH, Naoi M (2001c) Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann NY Acad Sci 939: 320-329
31. Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim M, Furukawa S, Nabeshima T, Naoi M (2004) N-Propargyl-1(R)- aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem Int 44: 393-400
32. Naoi M, Maruyama W, Dostert P, Hashizume Y, Nakahara D, Takahashi T, Ota M (1996) Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7- dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: Biochemical, pathological and behavioral studies. Brain Res 709: 285-295
33. Naoi M, Maruyama W, Nakao N, Ibi T, Sahashi K, Strolin Benedetti M (1998) (R)Salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes. Ann Neurol 43: 212-216
34. Naoi M, Maruyama W, Akao Y, Yi H (2002a) Mitochondria determine the survival and death in apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines. J Neural Transm [Suppl 109]: 607-621
35. Naoi M, Maruyama W, Akao Y, Yi H (2002b) Dopamine-derived endogenous N-methyl-(R)-salsolinol. Its role in Parkinson's disease. Neurotoxicol Tera 24: 579-591
36. Naoi M, Maruyama W, Nagy GM (2004) Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: Occurrence. Metabolism and function in human brains. NeuroToxicol 25: 193-204
37. Naoi M, Maruyama W, Shamoto-Nagai M, Yi H, Akao Y, Tanaka M (2005) Oxidative stress in mitochondria; decision to survival and death of neurons in neurodegenertaion. Mol Neurobiol 31: 81-93
38. O'Caroll AM, Fowler CJ, Phillips JP, Tobia I, Tipton KF (1988) The deamination of dopamine by human brain monoamine oxidase. Arch Pharmacol 322: 198-223
39. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561-566
40. Shih JC, Chen K, Ridd MJ (1999) Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 22: 197-217
41. Teitel S, O'Brien J, Brossi A (1972) Alkaloids in mammalian tissue II. Synthesis of (+) and (-)substituted 6,7-dihydroxy-1,2,3,4- tetrahydroisoquinolines. J Med Chem 15: 845-846
42. Tipton KF, Boyce S, O'Sullivan J, Davey GP, Healy J (2004) Monoamine oxidases: Certainties and uncertainties. Curr Med Chem 11: 1965-1982
43. Westlund KN, Denney RM, Rose RM, Abell CW (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25: 439-456
44. Wong WK, Chen K, Shih JC (2003) Decreased methylation and transcription repressor Sp3 up-regulated human monoamine oxidase (MAO) B expression during Caco-2 differentiation. J Biol Chem 278: 36227-36235
45. Yi H, Maruyama W, Akao Y, Takahashi T, Iwasa K, Youdim MBH, Naoi M (2006) N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 113: 21-32
46. Yi H, Akao Y, Maruyama W, Chen K, Shih J, Naoi M (2006) Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-Methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J Neurochem 96: 541-549
47. Youdim MBH, Gross A, Finberg JPM (2001) Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132: 500-506
48. Youdim MBH, Maruyama W, Naoi M (2005) Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drug Today 41: 369-391
49. Youdim MBH, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T (2005b) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurochem Res 79: 172-179